Effect of dapaglifozin on serum magnesium in HNF1β patients with renal hypomagnesemia

Phase 3

Recruiting

• Conditions: ADTKD-HNF1β HNF1β -related ADTKD; -related nephropathy; 10029149

• Registration Number: NL-OMON51437
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

- Genetically proven ADTKD-HNF1β disease
- Renal hypomagnesemia (serum magnesium < 0.70 mmol/l)
- Age 16 - 75 years
- Informed consent

Exclusion Criteria

- All other types of diabetes mellitus, including type 1 and type 2 diabetes
- History of kidney transplantation
- Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment
- Previous intolerance for an SGLT2 inhibitor
- Pregnancy or lactation
- Use of loop diuretics or thiazide diuretics and inability to discontinue
these medications before start of the trial
- eGFR < 30 ml/min/1,73m2
- Patients with severe hepatic impairment (Child-Pugh class C).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Change in serum magnesium </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Renal fractional magnesium excretion<br /><br>- Magnesium supplementation requirement<br /><br>- Symptoms scored by symptom questionnaire</p><br>